Treatment News : Tivicay (Dolutegravir) Is Approved in Europe

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » January 2014

Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


January 23, 2014

Tivicay (Dolutegravir) Is Approved in Europe

The European Commission has approved ViiV Healthcare’s integrase inhibitor Tivicay (dolutegravir) to treat HIV-positive adults and adolescents older than 12 in all nations of the European Union. Already approved by the U.S. Food and Drug Administration (FDA), Tivicay was studied in both treatment-experienced and treatment-naive people with HIV, including those with resistance to another integrase inhibitor, Isentress (raltegravir).

The approval was based on four pivotal Phase III clinical trials of 2,557 adults who received either Tivicay or Isentress in combination with other antiretrovirals (ARVs). A fifth study also examined Tivicay’s effects in children age 12 and older. The studies found Tivicay statistically superior to Isentress in two of the studies and non-inferior in a third.

Just 1 percent to 3 percent of participants discontinued Tivicay because of adverse side effects. The most common side effects were nausea (15 percent), diarrhea (16 percent) and headache (14 percent).

“Today’s approval of Tivicay is an important advance, opening the door to new treatment combinations for people living with HIV in Europe,” Dominique Limet, MD, chief executive officer of ViiV Healthcare, said in a release. “Tivicay’s clinical development program was only possible through partnerships with the people living with HIV and healthcare professionals who participated in it, and we aim to move forward together with them based on an absolute commitment to the HIV/AIDS global response.”

To read the ViiV release, click here.

Search: Tivicay, dolutegravir, European Commission, ViiV Healthcare, integrase inhibitor, Isentress, raltegravir, European Union, HIV, Dominique Limet.

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (0 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Has a pet helped you deal with your HIV?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.